ORIGINAL ARTICLE
Nanog expression in patients with squamous cell carcinoma of oropharynx in relation to immunohistochemical score
More details
Hide details
1
Department of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital in Krakow, Poland
2
Department of Tumour Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland
3
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
4
Department of Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland
Publication date: 2022-06-29
Pol J Pathol 2022;73(1):60-71
KEYWORDS
ABSTRACT
This study aimed to compare prognostic potential of Nanog expression analysed by three immunohistochemical scores in the group of 63 squamous cell carcinomas of oropharynx. Immunoreactivity of Nanog expression was analyzed by semiquantitative score, immunoreactive score and H-score. For all three scores, the cut-off points for Nanog overexpression and its lack, allowing for optimal separation of overall and disease free survival curves, were search by minimal p-value method. In semiquantitative score, the best separation of overall and disease free survival curves was obtain by cut-off point lack of staining vs. week/moderate/strong staining, although statistical significance was not reach (OS: HR = 1.016, p = 0.081, DFS: HR = 6.876, p = 0.061). The cut-off points for immunoreactive score and H-score were, respectively: 1 (OS: HR = 6.977, p = 0.014, DFS: HR = 6.002, p = 0.019) and 50 (OS: HR = 6.977, p = 0.014, DFS: HR = 6.002, p = 0.019). The cut-off points found for these two scores allow to identify the same subgroups of patients with lack of Nanog expression (11.1%) and its overexpression (88.9%). All patients with tumors characterized by lack of Nanog overexpression identifying by immunoreactive score and H-score survived 5 years without evidence of cancer progression. In multivariate analysis Nanog immunoreactivity analysed by QRS and IRS was independent prognostic factor for OS (HR = 10.195, p = 0.024). Immunohistochemical score using to distinguish Nanog overexpression or its lack has influence on prognostic potential of this biomarker.
REFERENCES (14)
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2.
Näsman A, Holzhauser S, Kostopoulou ON, et al. Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma. Viruses 2021; 13: 910.
3.
Mazibrada J, Longo L, Vatrano S, et al. Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis. New Microbiol 2014; 37: 129-143.
4.
Walcher L, Kistenmacher AK, Suo H, et al. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol 2020; 11: 1280.
5.
Rizzo D, Graziani C, Gallus R, et al. A. Stem cell markers in oral and oropharyngeal squamous cell carcinomas in relation to the site of origin and HPV infection: Clinical implications. Acta Otorhinolaryngologica Italica 2020; 40: 90-98.
6.
Pedregal-Mallo D, Hermida-Prado F, Granda-Díaz R, et al. Prognostic Significance of the Pluripotency Factors NANOG, SOX2, and OCT4 in Head and Neck Squamous Cell Carcinomas. Cancers (Basel) 2020; 12: 1794.
7.
de Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, et al. The Emerging Role of NANOG as an Early Cancer Risk Biomarker in Patients with Oral Potentially Malignant Disorders. J Clin Med 2019; 8: 1376.
8.
Rodrigo JP, Villaronga MÁ, Menéndez ST, et al. A Novel Role For Nanog As An Early Cancer Risk Marker In Patients With Laryngeal Precancerous Lesions. Sci Rep 2017; 7: 11110.
9.
Habu N, Imanishi Y, Kameyama K, et al. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer 2015; 15: 730.
10.
Lee HJ, Kang YH, Lee JS, et al. Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health 2015; 15: 153.
11.
Chang B, Park MJ, Choi SI, et al. NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy. Onco Targets Therp 2017; 10: 4625-4633.
12.
Biesaga B, Ko³odziej-Rzepa M, Janecka-Wid³a A, et al. Lack of CD44 overexpression and application of concurrent chemoradiotherapy with cisplatin independently indicate excellent prognosis in patients with HPV-positive oropharyngeal cancer. Tumour Biol 2021; 43: 99-113.
13.
Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6: 92.
14.
Tsai, LL, Yu, CC, Chang, YC, et al. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 621-628.